Hologic Reports $1B Q3 Revenue Raises Full-Year Profit Forecast

Hologic, a leading medical technology company focused on women's health, reported better-than-expected results for the third quarter of fiscal 2025, with GAAP revenue at $1.02 billion and non-GAAP earnings per share of $1.08, surpassing analyst forecasts. The company saw strong performance in its Diagnostics and Surgical segments, driven by robust demand for molecular diagnostic devices and surgical products, while its Breast Health segment experienced a decline due to weaker mammography equipment sales. Despite the headwinds in Breast Health, Hologic raised its full-year profit forecast and expects growth to accelerate in the fourth quarter, projecting adjusted earnings per share between $1.09 and $1.12 and revenue of $1.03 to $1.04 billion. CEO Stephen MacMillan highlighted progress toward improved top- and bottom-line growth, supported by tariff mitigation efforts and a rebound in the Breast Health business. The company also anticipates mid-single-digit organic revenue growth in 2026, excluding COVID-19 related revenue and divested businesses, signaling confidence in its ongoing recovery and expansion. Overall, Hologic's strong quarterly results and optimistic outlook have contributed to a notable rise in its stock price.